facebook
Cancer Care Associates | Dr Helen Ke

Dr Helen Ke

MBBS (Hons), Clin Dip Pall Med, FRACP
Medical Oncologist
Background

Dr Helen Ke is a medical oncologist with special interest in breast, genitourinary and thoracic cancers. Dr Ke was born in Sydney and obtained her medical degree from the University of New South Wales. She completed her subspecialty training in Medical Oncology at the Chris O’Brien Lifehouse (RPA) and Concord Hospitals. Dr Ke has furthermore obtained additional training (Clinical Diploma) in Palliative Medicine through the Royal Australasian College of Physicians, through which she further enhanced her skills in complex symptom management and delivery of compassionate and evidence-based care in challenging clinical situations.

Dr Helen Ke believes medical oncologists have a special duty for compassion, candour and sensitivity and upholds these principles in her practice. She is committed to the delivery of personalised care, using an evidence based and collaborative multi-disciplinary approach. Dr Ke spent 2 years as a Research Fellow with the Australian Rare Cancers Portal (ARC Portal, Royal Melbourne Hospital) and is the current Precision Oncology Fellow at The Prince of Wales Hospital, further developing her practice in this highly personalised, molecularly based approach to oncological practice.

She remains committed to development in research and teaching. Dr Helen Ke is a course coordinator for the Masters of Medicine program at Sydney University for the last 3 years, teaching post-graduate medical doctors, and is a PhD candidate at Sydney University investigating liquid biopsies, biomarkers and novel therapies in patients with mesothelioma.

Research, Awards and Teaching Interests
Awards
  • Asbestos Diseases Foundation of Australia (ADFA), PhD Scholarship (2021-2022)
    Topic: Investigating Immunotherapy Biomarkers and Novel Treatment Targets in Malignant Mesothelioma
  • Peer Reviewed Grant: SurFebruary Seed Funding Research Grant (2021)
    Topic: Investigation of DNA methylation as immunotherapy biomarkers in malignant mesothelioma
  • Griffith Hack 2022 Postgraduate Student Research Award (Runner Up) – ANZAC Research Institute
    Topic: The Immunohistochemical Expression and Clinical Relevance of Schlafen-11d and MGMT as a Combined Biomarker in Patients with Pleural Mesothelioma
  • Best of the Best Oral Presentation in Neuro-Oncology, Clinical Oncological Society of Australia (COSA) ASM (2009)
    Topic: Screening for Cognitive Impairment in Primary Brain Tumour: Is the Montreal Cognitive Assessment a more Sensitive Tool than the Mini Mental State Examination?
    Research
Published Papers
  • Ke H, Kao S, van Zandwijk N, Rasko J. Circulating tumor cell detection may offer earlier diagnosis in patients suspected of asbestos-related lung cancer. Lung Cancer (Accepted for Publication; In Proof). 2024 May
  • Shi H, Zhang L, Yu TK, Zhuang L, Ke H, Johnson B, Rath E, Lee K, Klebe S, Kao S, Qin KL, Pham HNT, Vuong Q, Cheng YY. Leptospermum extract (QV0) suppresses pleural mesothelioma tumor growth in vitro and in vivo by mitochondrial dysfunction associated apoptosis. Front Oncol. 2023 Jul 5;13:1162027. doi: 10.3389/fonc.2023.1162027. PMID: 37476375; PMCID: PMC10354640.
  • Shi H, Rath EM, Lin RCY, Sarun KH, Clarke CJ, McCaughan BC, Ke H, Linton A, Lee K, Klebe S, Maitz J, Song K, Wang Y, Kao S, Cheng YY. 3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies. Front Oncol. 2022 Aug 26;12:973576. doi: 10.3389/fonc.2022.973576. PMID: 36091141; PMCID: PMC9462830.
  • Davis A, Ke H, Kao S, Pavlakis N. An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma. Lung Cancer (Auckl). 2022 Mar 2;13:1-12. doi: 10.2147/LCTT.S288535. PMID: 35264891; PMCID: PMC8900635.
  • Hyland, R. A, Chrzanowska, A, Hannaford-Turner, K., Davis, A., Ke, H., Bradbury, L., Nagrial, A., McCaughan, B, Hui, R., van Zandwijk, N., Takahashi, K., Kao, S. (2022). “Asbestos-related lung cancer: Clinical characteristics and survival outcomes in an Australian cohort seeking workers compensation.” Asia‐Pacific Journal of Clinical Oncology.
  • Ke, H., Kao, S., Lee, K., Takahashi, K., Goh, H.P. and Linton, A. (2021) “The minimum standard of care for managing malignant pleural mesothelioma in developing nations within the Asia‐Pacific Region” Asia‐Pacific Journal of Clinical Oncology.
  • Ke, H., Gill, A.J., McKenzie, C., Kench, J.G., et al. (2021) “Malignant Peritoneal Mesothelioma With EWSR1-ATF1 Fusion: A Case Report” JTO Clin Res Rep 2(11): 100236.
  • Mizrahi D, Park SB, Li T, Timmins HC, Trinh T, Au K, Battaglini E, Wyld D, Henderson RD, Grimison P, Ke H, Geelan-Small P, Marker J, Wall B, Goldstein D. “Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy”. JAMA Netw Open. 2021 Feb 1;4(2):e2036695.
  • Ke, H., Lee, K., Clarke, C., Zhuang, L. et al. (2023). “The Immunohistochemical Expression and Clinical Relevance of Schlafen-11 and MGMT as a Combined Biomarker in Patients with Malignant Pleural Mesothelioma.”, (Under Review)
  • Ke H, Koh E, Simpson G, Whiting D. Screening for Cognitive Impairment in Primary Brain Tumour: Is the Montreal Cognitive Assessment a more Sensitive Tool than the Mini Mental State Examination?. Asia Pacific Journal of Clinical Oncology. 2009; 5 {Suppl 2}: A173.
Book Chapter
  • Ke H., Kao. S., Hui GP, Linton A (2021). Section A: Medical, Chapter 3 – Treatment of Mesothelioma. Action Toolkit for the Elimination of Asbestos-Related Disease – A Guide for Developing Countries, (2021), Asbestos Diseases Research Institute, Sydney, Australia.
    Oral Conference Presentations
  • Ke H, Zhuang L, Cheng YY, Clarke C, Lee K, Heller G, McCaughan B, Linton A, Kao S. The Immunohistochemical Expression and Clinical Relevance of Schlafen-11 and MGMT as a Combined Biomarker in Patients with Malignant Pleural Mesothelioma. Thoracic Oncology Society of Australia (TOGA) 2021, Sydney. (Oral).
  • Ke H, Koh E, Simpson G, Whiting D. Screening for Cognitive Impairment in Primary Brain Tumour: Is the Montreal Cognitive Assessment a more Sensitive Tool than the Mini Mental State Examination? Clinical Oncological Society of Australia (COSA) AGM 2009, Gold Coast. (Oral) – Awarded Best of the Best Abstract in Neuro-Oncology
  • Koh E, Ke H, Simpson G, Whiting D. Screening for Cognitive Impairment in Primary Brain Tumour: Is the Montreal Cognitive Assessment a more Sensitive Tool than the Mini Mental State Examination? European Association of Neuro-oncology (EANO) Meeting 2010, Maastricht. (Oral)
Teaching
  • Unit of Study Coordinator, Masters of Medicine (Internal Medicine), University of Sydney
    Basic Oncology Course (April 2021 – Current)
Professional Memberships
  • American Society of Clinical Oncology
  • European Society of Medical Oncology
  • Medical Oncology Group of Australia
  • Thoracic Oncology Group of Australia